[{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Asahi Kasei Finechem","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Asahi Kasei Finechem","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asahi Kasei Finechem \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Asahi Kasei Finechem \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.51000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Astellas Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":1.0900000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":1.0700000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Avir Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Avir Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Avir Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":1.0700000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.72999999999999998,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.60999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.72999999999999998,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Asahi Kasei Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Asahi Kasei Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Asahi Kasei Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Knight Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Knight Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Knight Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Basilea Pharmaceutica","amount2":0.72999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.72999999999999998,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Basilea Pharmaceutica \/ Pfizer Inc"},{"orgOrder":0,"company":"Jeffrey Jenks","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jeffrey Jenks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeffrey Jenks \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Jeffrey Jenks \/ Astellas Pharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"systemic antifungals (miconazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Cresemba
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
